| Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma |
NCT03159052: Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes |
|
|
| Unknown status | 3 | 450 | RoW | SHR3824, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Type 2 Diabetes Mellitus | 10/18 | 06/19 | | |
NCT04390295: Efficacy and Safety of SHR3824 in Combination With Metformin in Subjects With Type 2 Diabetes |
|
|
| Unknown status | 3 | 450 | RoW | Placebo, SHR3824, metformin | Jiangsu HengRui Medicine Co., Ltd. | Type 2 Diabetes Mellitus | 05/20 | 05/20 | | |
NCT04667143: Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy |
|
|
| Not yet recruiting | 3 | 760 | NA | Retagliptin, Henagliflozein, metformin XR | Jiangsu HengRui Medicine Co., Ltd. | Diabetes Mellitus, Type II | 09/22 | 10/22 | | |
| Not yet recruiting | 3 | 100 | RoW | placebo, Henagliflozin 5Mg Tab | Beijing Anzhen Hospital | Atrial Fibrillation | 09/23 | 09/23 | | |
ChiCTR2400080435: A Study to Assess the Effects of the Endothelin Receptor Antagonist Ambrisentan, the SGLT2 Inhibitor Henagliflozin, and Their Combination in Patients With IgA Nephropathy: a Single-center, Randomized, Open-label, Cross-over Clinical Trial |
|
|
| Not yet recruiting | 3 | 60 | | "ambrisentan"-"henagliflozin"-"ambrisentan+henagliflozin"; "ambrisentan"-"ambrisentan+henagliflozin"-"henagliflozin"; "henagliflozin"-"ambrisentan"-"ambrisentan+henagliflozin"; "henagliflozin"-"ambrisentan+henagliflozin"-"ambrisentan"; "ambrisentan+henagliflozin"-"henagliflozin"-"ambrisentan"; "ambrisentan+henagliflozin"-"ambrisentan"-"henagliflozin" | Peking University First Hospital; Peking University First Hospital, National Science Fund for Distinguished Young Scholars (No. 81925006) | IgA Nephropathy | | | | |
